New neplanocin analogues. VIII. Synthesis and biological activity of 6'- C-ethyl, -ethenyl, and -ethynyl derivatives of neplanocin A

Chemical and Pharmaceutical Bulletin

Volumn 45, Issue 7, 1997, Pages 1163-1168

  Shuto, Satoshi ^a   Obara, Takumi ^b   Saito, Yasuyoshi ^b   Yamashita, Kanako ^b   Tanaka, Motohiro ^c   Sasaki, Takuma ^c   Andrei, Graciela ^d   Snoeck, Robert ^d   Neyts, Johan ^d   Padalko, Elisabeth ^d   Balzarini, Jan ^d   De Clercq, Erik ^d   Matsuda, Akira ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

^b ASAHI CHEMICAL INDUSTRY CO   (Japan)

^c KANAZAWA UNIVERSITY   (Japan)

^d REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

Adenosine deaminase; Antiviral agent; Modified Mosher's method; Neplanocin A; S adenosylhomocysteine hydrolase

Indexed keywords

6' C ETHYNYLNEPLANOCIN A; ANTIVIRUS AGENT; NEPLACIN DERIVATIVE; NEPLANOCIN A; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CHEMICAL REACTION; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG SCREENING; DRUG SYNTHESIS; NONHUMAN; VACCINIA VIRUS; VESICULAR STOMATITIS VIRUS;

EID: 0030790479     PISSN: 00092363     EISSN: None     Source Type: Journal    
DOI: 10.1248/cpb.45.1163     Document Type: Article

References (40)

1. This paper constitutes Part 154 of Nucleosides and Nucleotides. Part 153: Aoyagi M., Ueno Y., Ono A., Matsuda A., BioMed. Chem. Lett., 6, 1573-1576 (1996).
2. Ueland P. M., Pharmacol. Rev., 34, 223-253 (1982).
3. Wolfe M. S., Borchardt R. T., J. Med. Chem., 34, 1521-1530 (1991).
4. a) De Clercq E., Biochem. Pharmacol., 36, 2567-2575 (1987);
5. b) Snoeck R., Andrei G., Neyts J., Schols D., Cools M., Balzarini J., De Clercq E., Antiviral Res., 21, 197-216 (1993);
6. c) De Clercq E., Nucleosides Nucleotides, 13, 1271-1295 (1994);
7. d) De Clercq E., Bergstrom D. E., Holy A., Montgomery J. A., Antiviral Res., 4, 119-133 (1984):
8. e) Matsuda A., Kosaki H., Yoshimura Y., Shuto S., Ashida N., Konno K., Shigeta S., BioMed. Chem. Lett., 5, 1685-1688 (1995).
9. Cools M., De Clercq E., Biochem. Pharmacol., 38, 1061-1067 (1989).
10. a) Yaginuma S., Muto N., Tsujino M., Sudate Y., Hayashi M., Otani M., J. Antibiot., 34, 359-366 (1981);
11. b) Hayashi M., Yaginuma S., Yoshioka H., Nakatsu K., ibid., 34, 675-680 (1981).
12. De Clercq E., Antimicrob. Agents Chemother., 28, 84-89 (1985).
13. a) Glazer R. I., Knode M. C., J. Biol. Chem., 259, 12964-12969 (1984);
14. b) Inaba M., Nagashima S., Tsukagoshi S., Sakurai Y., Cancer Res., 46, 1063-1067 (1986);
15. c) Hoshi A., Yoshida M., Iigo M., Tokuzen R., Fukukawa K., Ueda T., J. Pharmacobio-Dyn., 9, 202-206 (1986);
16. d) Hasobe M., McKee J. G., Borchardt R. T., Antimicrob. Agents Chemother., 33, 828-834 (1989);
17. e) De Clercq E., Cools M., Balzarini J., Biochem. Pharmacol., 38, 1771-1778 (1989).
18. a) Ransohoff R. M., Narayan P., Ayes D. F., Rottaman F. M., Nilsen T. W., Antiviral Res., 7, 317-327 (1987);
19. b) Borchrdt R. T., Keller B. T., Patel-Thombre U., J. Biol. Chem., 259, 4353-4358 (1984).
20. Tsujino M., Yaginuma S., Fujii T., Hayano K., Matsuda T., Watanabe T., Abe J., Current Chemotherapy and Infectious Disease, 3, 1559 (1981).
21. a) Shuto S., Obara T., Toriya M., Hosoya M., Snoeck R., Andrei G., Balzarini J., De Clercq E., J. Med. Chem., 35, 324-331 (1992);
22. b) Shigeta S., Mori S., Baba M., Ito M., Honzumi K., Nakamura K., Oshitani H., Numazaki Y., Matsuda A., Obara T., Shuto S., De Clercq E., Antimicrob. Agents Chemother., 36, 435-439 (1992);
23. c) Shuto S., Obara T., Kosugi Y., Toriya M., Yaginuma S., Shigeta S., Matsuda A., BioMed. Chem. Lett., 4, 605-608 (1994);
24. d) Shuto S., Obara T., Itoh H., Kosugi Y., Saito Y., Toriya M., Yaginuma S., Shigeta S., Matsuda A., Chem. Pharm. Bull., 42, 1688-1690 (1994);
25. e) Obara T., Shuto S., Saito Y., Toriya M., Ogawa K., Yaginuma S., Shigeta S., Matsuda A., Nucleosides Nucleotides, 15, 1157-1167 (1996);
26. f) Shuto S., Obara T., Saito Y., Andre G., Snoeck R., De Clercq E., Matsuda A., J. Med. Chem., 39, 2392-2399 (1996);
27. g) Obara T., Shuto S., Saito Y., Snoeck R., Andrei G., Barzarini J., De Clercq E., Matsuda A., ibid., 39, 3847-3852 (1996);
28. h) Shuto S., Obara T., Yaginuma S., Matsuda A., Chem. Pharm. Bull., 45, 138-142 (1997).
29. For example: a) Borcherding D. R., Narayanan S., Hasobe M., McKee J. G., Keller B. T., Borchardt R. T., J. Med. Chem., 31, 1729-1738 (1988);
30. b) Tseng C. K. H., Marquez V. E., Fuller R. W., Goldstein B. M., Haines D. R., McPherson H., Parsons J. L., Shannon W. M., Arnett G., Hollingshead M., Driscoll J. S., ibid., 32, 1442-1446 (1989);
31. c) Hasobe M., McKee J. G., Borcherding D. R., Borchardt R. T., Antimicrob. Agents Chemother., 31, 1849-1851 (1987).
32. Ohtani I., Kusumi T., Kashman Y., Kakisawa H., J. Am. Chem. Soc., 113, 4092-4096 (1991).
33. Koyama H., Tsuji M., Biochem. Pharmacol., 32, 3547-3553 (1983).
34. A computer program for the solution and refinement of crystal structures from X-ray diffraction data, Mac Science Co., Ltd., version 6.1, 1994.
35. Altomare A., Cascarano G., Giacovazzo C., Guagliardi A., Burla M. C., Polidori G., Camalli M., J. Appl. Cryst., 27, 435-436 (1994).
36. a) Schols D., De Clercq E., Balzarini J., Baba M., Witvrouw M., Hosoya M., Andrei G., Snoeck R., Neyts J., Pauwels R., Nagy M., Gyorgyi-Edelenyi J., Machovich R., Horvath I., Low M., Gorog S., Antiviral Chem. Chemother., 1, 233-240 (1990);
37. b) De Clercq E., Descamps J., Verhelst G., Walker R. T., Jones A. S., Torrence P. F., Shugar D., J. Infect. Dis., 141, 563-574 (1980);
38. c) De Clercq E., Holy A., Rosenberg I., Sakuma T., Balzarini J., Maudgal P. C., Nature (London), 323, 464-467 (1986);
39. d) Balzarini J., Naesens L., Herdewijn P., Rosenberg I., Holy A., Pauwels R., Baba M., Johns D. G., De Clercq E., Proc. Natl. Acad. Sci. U.S.A., 86, 332-336 (1989);
40. e) Cools M., Balzarini J., De Clercq E., Mol. Pharmacol., 39, 718-724 (1991).